title: Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
abstract: Sequence analysis of human immunodeficiency virus type 1 (HIV-1) from 74 persons with acute infections identified eight strains with mutations in the reverse transcriptase (RT) gene at positions 41, 67, 68, 70, 215, and 219 associated with resistance to the nucleoside analogue zidovudine (AZT). Follow-up of the fate of these resistant HIV-1 strains in four newly infected individuals revealed that they were readily replaced by sensitive strains. The RT of the resistant viruses changed at amino acid 215 from tyrosine (Y) to aspartic acid (D) or serine (S), with asparagine (N) as a transient intermediate, indicating the establishment of new wild types. When we introduced these mutations and the original threonine (T)-containing wild type into infectious molecular clones and assessed their competitive advantage in vitro, the order of fitness was in accord with the in vivo observations: 215Y < 215D = 215S = 215T. As detected by real-time nucleic acid sequence-based amplification with two molecular beacons, the addition of AZT or stavudine (d4T) to the viral cultures favored the 215Y mutant in a dose-dependent manner. Our results illustrate that infection with nucleoside analogue-resistant HIV leads in newly infected individuals to mutants that are sensitive to nucleoside analogues, but only a single mutation removed from drug-resistant HIV. Such mutants were shown to be transmissible, stable, and prone to rapid selection for resistance to AZT or d4T as soon as antiretroviral therapy was administered. Monitoring of patients for the presence of new HIV-1 wild types with D, S, or N residues at position 215 may be warranted in order to estimate the threat to long-term efficacy of regimens including nucleoside analogues.
authors.affiliation: Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. ronde@amc.uva.nl
authors.forename: A
authors.initials: A
authors.lastname: de Ronde
authors.forename: M
authors.initials: M
authors.lastname: van Dooren
authors.forename: L
authors.initials: L
authors.lastname: van Der Hoek
authors.forename: D
authors.initials: D
authors.lastname: Bouwhuis
authors.forename: E
authors.initials: E
authors.lastname: de Rooij
authors.forename: B
authors.initials: B
authors.lastname: van Gemen
authors.forename: R
authors.initials: R
authors.lastname: de Boer
authors.forename: J
authors.initials: J
authors.lastname: Goudsmit
mesh_terms: D004352:Drug Resistance, Microbial / Q000235:genetics; D019143:Evolution, Molecular; D005814:Genes, Viral; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000737:chemistry / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000502:physiology; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D021161:Self-Sustained Sequence Replication; D014776:Virus Cultivation; D014779:Virus Replication; D015215:Zidovudine / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D054303:HIV Reverse Transcriptase